Search for Vaccine/Treatment

March 25, 2020

“As the world anxiously awaits a possible vaccine to prevent thousands of people from getting infected from COVID-19 virus, around 35 pharmaceutical companies and institutes are racing against time to create such a vaccine. At least four such companies, have already started testing in animals. The science journal of American Association of Advancement in Science (AAAS) reports that Boston based biotech firm, Moderna Therapeutics is speeding the vaccine through an internal safety trial in collaboration with National Institute of Allergy and Infectious Disease.”

March 25, 2020

“COVID-19 began infecting the human race in Wuhan, China, and the nation is now upping the ante in a search for a cure. The effort from China to find a cure began on March 16 and officials believe the trials will continue through to the end of the year. A staff member from the country’s Clinical Trial Registry said: “Volunteers of the COVID-19 phase one trial have already started receiving the vaccine.” Researchers will trial on 108 participants, aged between 18 and 60 who are all from the Wuhan region. All participants will be split into three groups, who will be given different dosages of the vaccine. As little is known about the virus and its relatively new emergence, the progress of the vaccine will very much be trial and error until scientists can make the discovery.”

March 16, 2020

“A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.”

March 15, 2020

“The first participant in a clinical trial for a vaccine to protect against the new coronavirus will receive an experimental dose on Monday, according to a government official. The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. The official who disclosed plans for the first participant spoke on condition of anonymity because the move has not been publicly announced. Public health officials say it will take a year to 18 months to fully validate any potential vaccine. Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There’s no chance participants could get infected from the shots, because they don’t contain the virus itself.”

March 2, 2020

“Taiwan’s Development Center for Biotechnology (DCB) announced on Monday (March 2) that it has successfully completed the synthesis of favilavir, a drug that could be potentially used to treat Wuhan coronavirus, The DCB said that in the future, it would work with cGMP manufacturers to produce sufficient antiviral drugs for patients, according to a CNA report. DCB deputy director Chuang Shih-hsien (莊士賢) said that the center focused on synthesizing favilavir, which was developed by a Japanese pharmaceutical company and approved for sale in Japan in March 2014. The drug is mostly used to treat flu patients who do not respond to Tamiflu and Relenza Rotadisk, the report said.”

March 1, 2020

“The effort by the U.S. Centers for Disease Control and Prevention to protect Americans from the new coronavirus has been hamstrung by a flawed test for the disease and limited access to a reliable analysis, resulting in significant delays to determine which people have the virus, according to officials and experts. But the Food and Drug Administration announced Saturday that labs and hospitals across the nation will now be able to conduct the test and won’t have to wait for results from the CDC.”

February 27, 2020

“”Hope for treating the novel coronavirus could be on the horizon, as the first US study of a drug to treat the illness is underway. So far, there is no cure or vaccine for the virus, which has infected more than 80,000 people and killed more than 2,700 worldwide in the past few months. News of the drug testing came Tuesday, just as a federal health official warned that the virus will eventually start spreading in US communities.”

February 26, 2020

“Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19. Novavax created the COVID-19 vaccine candidates using its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidate to enhance immune responses. “Our previous experience working with other corona viruses, including both MERS and SARS, allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.”

February 24, 2020

U.S. President Donald Trump will seek $2.5 billion from Congress to fight the coronavirus epidemic and U.S. and South Korean militaries are considering scaling back joint training as the virus spreads in Europe and the Middle East. Countries around the world are stepping up efforts to prevent a pandemic of the flu-like virus that originated from China late last year and has now infected more than 80,000 people, 10 times more cases than the SARS coronavirus.

Drugmaker Moderna Inc. has shipped the first batch of its rapidly developed coronavirus vaccine to U.S. government researchers, who will launch the first human tests of whether the experimental shot could help suppress the epidemic originating in China. Moderna on Monday sent vaccine vials from its Norwood, Mass., manufacturing plant to the National Institute of Allergy and Infectious Diseases in Bethesda, Md., the company said.

February 19, 2020

Researchers from The University of Texas at Austin and the National Institutes of Health have made a critical breakthrough toward developing a vaccine for the 2019 novel coronavirus by creating the first 3D atomic scale map of the part of the virus that attaches to and infects human cells. Mapping this part, called the spike protein, is an essential step so researchers around the world can develop vaccines and antiviral drugs to combat the virus. The paper was published Wednesday, Feb. 19 in the journal Science.

February 16, 2020

According to the country’s direct train, this vaccine was jointly designed and developed by the Chinese Centers for Disease Control and Prevention, Shanghai Tongji University School of Medicine, and Shanghai Biotechnology Co., Ltd., which provided samples for production of vaccines. On Sunday, samples of the new vaccine were injected into more than 100 healthy mice.

February 15, 2020

Inovio Pharmaceuticals said that it has produced a pre-clinical vaccine to fight the deadly COVID-19 coronavirus at its lab in San Diego. The company, based in Plymouth Meeting, Pa., used its proprietary DNA-based technology platform to design the synthetic vaccine within hours of getting the genetic sequencing of the virus. Inovio did not respond to phone calls and emails seeking comment. But in an interview with Yahoo Finance on Friday, Chief Executive Dr. J. Joseph Kim said that the company aims to test its vaccine in the U.S. and China as early as this summer.

February 13, 2020

As the scientific community scrambles to find a drug that can effectively treat tens of thousands of patients sickened by a new respiratory virus, they are trying some surprising remedies: medicines targeting known killers like HIV, Ebola and malaria. American drugmakers have shipped two antiviral medications to China as doctors and public health officials there seek an effective treatment for patients sickened by the novel coronavirus, which has recently been named COVID19.

February 11, 2020

The first vaccine targeting China’s coronavirus could be available in 18 months, “so we have to do everything today using available weapons”, World Health Organization chief Tedros Adhanom Ghebreyesus said in Geneva on Tuesday. He said the virus had been named COVID-19, explaining that it was important to avoid stigma and that other names could be inaccurate.

February 09, 2020

The first case of novel coronavirus in the Philippines – a Chinese tourist from Wuhan who had been travelling with a man who died of the virus – is no longer showing symptoms and may be discharged soon. The last test on the 38-year-old woman, conducted on 6 February, showed she was negative for the virus, according to the health department. Two consecutive negative tests are required before a patient may be discharged.

China is spending at least $10 billion to control the coronavirus outbreak and reaching out for medical supplies as the first wave of international experts heads to the disease’s epicenter.
A cruise ship in Japan with 70 victims has the most infections outside China. Another exhibitor quits an industry event in Barcelona. Scientists modeling the virus in Wuhan predict infections may peak this month. The illness has now killed more people than SARS.

February 07, 2020

The 2019 novel coronavirus (2019-nCoV) outbreak is a major challenge for clinicians. The clinical course of patients remains to be fully characterised, little data are available that describe the disease pathogenesis, and no pharmacological therapies of proven efficacy yet exist. Corticosteroids were widely used during the outbreaks of severe acute respiratory syndrome (SARS)-CoV1 and Middle East respiratory syndrome (MERS)-CoV,2 and are being used in patients with 2019-nCoV in addition to other therapeutics.

February 05, 2020

The scientist leading the UK’s research into a coronavirus vaccine says his team have made a significant breakthrough by reducing a part of the normal development time from “two to three years to just 14 days”.
Professor Robin Shattock, head of mucosal infection and immunity at Imperial College London, said he is now at the stage to start testing the vaccine on animals as early as next week with human studies in the summer if enough funding is secured.

February 04, 2020

In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China. The initial cases were linked to exposures in a seafood market in Wuhan. As of January 27, 2020, the Chinese authorities reported 2835 confirmed cases in mainland China, including 81 deaths.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization.

February 03, 2020

Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand.

February 02, 2020

A Chinese woman infected with the new coronavirus showed a dramatic improvement after she was treated with a cocktail of antivirals used to treat flu and HIV, Thailand’s health ministry said on Sunday.

January 31, 2020

NIAID-funded scientists are exploring ways to treat and prevent human coronavirus infections by working to develop new antibodies, drugs, and vaccines that block entry to cells, delay the immune system response, or block viral replication. For 2019-nCoV, NIAID scientists, working in Bethesda, Md., and Hamilton, Mont., are preparing to test the antiviral drug remdesivir, which has shown promise against other coronaviruses in animal models.

Gilead is working closely with global health authorities to respond to the novel coronavirus (2019-nCoV) outbreak through the appropriate experimental use of our investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and Human Services (DHHS), the China CDC and National Medical Product Administration (NMPA), the World Health Organization (WHO), and the U.S. National Institute of Allergies and Infectious Diseases (NIAID), and along with individual researchers and clinicians, Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting 2019-nCoV.

January 29, 2020

Recently a novel coronavirus (2019-nCoV) has emerged from Wuhan, China, causing symptoms in humans similar to those caused by SARS coronavirus (SARS-CoV). Since SARS-CoV outbreak in 2002, extensive structural analyses have revealed key atomic-level interactions between SARS-CoV spike protein receptor-binding domain (RBD) and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of SARS-CoV.

Sign Up for Newsletter

Footer Newsletter

World Response

Search for Vaccine